Bevacizumab Improves Survival For Patients With Advanced Breast Cancer

Armen Hareyan's picture
Advertisement

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy. The study, published in the December 27th issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.

Advertisement

Rush University Medical Center participated in the clinical trial which was sponsored by the National Cancer Institute and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The study of 722 women with recurrent (metastatic) breast cancer found that the women who received Avastin in combination with standard chemotherapy had a doubling of delay in worsening of their cancer by approximately five months, on average, compared to patients treated with chemotherapy alone. Those on Avastin had progression-free survival of 11.3 months compared to 6 months on standard chemotherapy alone.

"This therapy is a one-two punch! You hit the tumor with the chemo and sabotage new blood vessel growth by restricting

Advertisement